Trial Profile
A Single-Center, Randomized, Double-Blind, Phase III Comparison of the Efficacy and Safety of Quetiapine Fumarate (Oral Extended Release Tablets) to Placebo in Social Phobia Patients and Changes in Their Vasodilatory Response to Methyl-Nicotinate.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Quetiapine (Primary)
- Indications Social phobia
- Focus Pharmacodynamics
- 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Aug 2011 Planned end date changed from 1 Jun 2009 to 1 Sep 2011 as reported by ClinicalTrials.gov.
- 03 Aug 2011 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.